You are here: Industry Insights > Samsung Biologics

News List

Samsung Biologics to buy out Biogen's stake in Samsung Bioepis CPhIonline
January 29, 2022
Samsung Biologics has reached an agreement for the buyout of Biogen’s stake in the Samsung Bioepis joint venture for USD $2.3 billion.
Samsung Biologics to acquire Biogen’s stake in Samsung Bioepis for $2.3bn Pharmaceutical-Technology
January 29, 2022
Biogen is eligible to receive up to $50m from Samsung Biologics on meeting some commercial milestones.
Samsung Biologics and AstraZeneca expand manufacturing partnership to include COVID-19 and cancer therapies CPhIonline
December 16, 2021
CDMO currently manufacturing LAAB combination treatment and will start on cancer immunotherapy product from next year.
Samsung Biologics and AstraZeneca expand deal to include Covid-19 treatment Pharmaceutical-Technology
December 15, 2021
Samsung Biologics and AstraZeneca have expanded a strategic biopharmaceutical production partnership to include therapies for Covid-19 and cancer.
Samsung Biologics and AstraZeneca expand strategic manufacturing partnership to include COVID-19 and cancer therapy prnasia
December 14, 2021
Samsung Biologics (207940.KS), the world's leading contract development and manufacturing organization, continues its strategic biopharmaceutical manufacturing collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN).
GreenLight Biosciences and Samsung Biologics announce collaboration to build capacity for messenger RNA Vaccine Manufacturing prnasia
November 25, 2021
GreenLight Biosciences (Nasdaq: ENVI), a biotechnology company dedicated to making ribonucleic acid (RNA) products affordable and accessible for human health and agriculture, and Environmental Impact Acquisition Corp...
Samsung Biologics and Kineta strike cancer immunotherapy development and manufacturing deal cphi-online
July 22, 2021
Samsung to provide end-to-end CDMO services to advance Kineta's novel anti-VISTA antibody for the treatment of solid tumours
Samsung Biologics expands portfolio with mRNA vaccine manufacturing capability cphi-online
June 03, 2021
The additional manufacturing suite at the CDMO's Songdo site is anticipated to be ready for cGMP operations within the first half of 2022
Samsung Biologics scores large-scale ublituximab manufacturing deal cphi-online
May 24, 2021
TG Therapeutics secures long-term capacity to meet anticipated demand for promising investigational glycoengineered monoclonal antibody
Samsung Biologics Reports First Quarter 2021 Financial Results prnasia
April 28, 2021
Samsung Biologics, the world's leading contract development and manufacturing organization, today announced financial results for the first quarter of fiscal 2021.

Previous page 1 2 3 4 5 6 Next page